Jack W. Callicutt

Jack W. Callicutt appears in our data through filings on Galectin Therapeutics Inc shares, published by SEC (Form 4). We count 59 filings; the first trade dates from 4 April 2018 and the latest from 6 January 2026.

Market trades split into 2 purchases (€14k) and 29 sales (€3.4M). The net balance comes to €3.4M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 28 option exercises. Since January 2026: no purchases and 3 sales on the market.

Most recently, on 6 January 2026, the filings show an open-market sale worth €50k in Galectin Therapeutics Inc. The last insider purchase was made public on 17 November 2022, 1,437 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.